The global facial aesthetics market revenue was around US$ 7.19 billion in 2022 and is estimated to reach US$ 26.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 15.5% during the forecast period from 2023 to 2031.
Facial aesthetics is a non-invasive aesthetic procedure performed to treat skin conditions such as acne, scars, wrinkles, hyperpigmentation, stretch marks, and dark skin. There are various facial aesthetic procedures such as chemical peels, cosmetic implants, botulinum toxin, dermal fillers, and microdermabrasion, which are utilized to enhance aesthetic appearance.
Market Driving Factors
Surging demand for clinically proven and prescription products is estimated to boost the market. This is due to the consumers choosing treatments with clinically proven records and mostly desire to visit a dermatologist for the selected facial treatment rather than going to beauty spa centers. In addition, they are also surging opting for prescribed products as compared to traditional topical treatment products and over-the-counter drugs. Therefore, the surge in the production of clinically proven products connected with prescription-based products is estimated to generate substantial demand for facial aesthetic formulations.
Adoption and acceptance of facial aesthetics in the female population are estimated to drive market growth. This is mainly due to the non-invasive facial aesthetic procedures that are highly famous among women owing to surging levels of self-consciousness and a desire to be attractive.
The high prices associated with facial aesthetic procedures are estimated to hamper the market.
Regional Analysis
North America dominated the market in terms of revenue and is expected to maintain its dominance. This can be majorly attributed to the surge in the number of botulinum toxin procedures, the rise in the number of approvals for facial aesthetics products, the existence of the facial aesthetics industry, and advances in the aesthetic and medical sector in the region.
Asia-Pacific is predicted to dominate the market in terms of the growth rate. This is due to the surge in female populations, increase in awareness among the young population regarding the availability of various facial aesthetic procedures, increase in healthcare expenditures, and increase in adoption of facial aesthetic products.
Segmentation Insights
Product Insight
The botulinum toxin segment is estimated to dominate the market in terms of growth rate. This is due to the rise in R&D initiatives for the development of cutting-edge botulinum toxin products and the surge in demand for therapeutic and aesthetic indications of botulinum toxin.
Application Insight
The facial line correction treatment segment dominates the market in terms of the largest shares. This is mainly owing to the surge in the geriatric population who expand facial lines and the increase in demand for facial line correction treatment procedures.
End User Insight
The specialty & dermatology clinics segment is estimated to dominate the market in terms of revenue growth. This is due to the increase in the prevalence of skin conditions such as acne, hyperpigmentation, stretch marks, and scars, and the surge in the number of experts who offer treatment of facial aesthetics in dermatology clinics.
The hospital segment dominated the market in terms of revenue and is expected to continue its dominance. This can be attributed to the surge in the number of hospitals to conduct facial aesthetic processes, and the rise in expenses by governments to enhance the aesthetic centers in hospitals.
Prominent Companies
Segmentation Outline
The global facial aesthetics market segmentation focuses on the Product, Application, End User, and Region.
By Product
By Application
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL FACIAL AESTHETICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: FACIAL AESTHETICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL FACIAL AESTHETICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL FACIAL AESTHETICS MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 DERMAL FILLERS
5.3 BOTULINUM TOXIN
5.4 MICRODERMABRASION
5.5 CHEMICAL PEELS
5.6 OTHERS
6 GLOBAL FACIAL AESTHETICS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 FACIAL LINE CORRECTION TREATMENT
6.3 SCAR TREATMENT
6.4 LIP ENHANCEMENT
6.5 RESTORATION OF VOLUME OR FULLNESS
6.6 OTHERS
7 GLOBAL FACIAL AESTHETICS MARKET, BY END USER
7.1 OVERVIEW
7.2 SPECIALTY AND DERMATOLOGY CLINICS
7.3 HOSPITALS
7.4 OTHERS
8 GLOBAL FACIAL AESTHETICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL FACIAL AESTHETICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 BAUSCH HEALTH COMPANIES INC.
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 IPSEN
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ANIKA THERAPEUTICS INC.
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 JOHNSON AND JOHNSON
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 VITAL ESTHETIQUE
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 FOTONA D.O.O
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 EVOLUS INC.
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 MERZ PHARMA
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 SINCLAIR PHARMACEUTICALS LIMITED
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 ELAN AESTHETICS
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 REVANCE THERAPEUTICS
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 ABBVIE INC
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 GALDERMA LABORATORIES
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 CYNOSURE
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 CUTERA INC.
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 TEOXANE
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.17 CANDELA SYNERON
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved